Piramal Pharma Share Price hits a high of Rs 243, may create a new high or may reverse, know the opinion of market experts
Piramal Pharma’s share price closed at Rs 231.44 on September 10, 2024, up 6.49% from the previous day’s close of Rs 217.34. The stock hit a 52-week high of Rs 244 during the day’s trading session. The surge in share price comes after the company reported its quarterly results for the period ending June 30, 2024.
Main Points
Piramal Pharma Q1 FY2025 Results
In the first quarter of the financial year 2024-25, Piramal Pharma reported a consolidated income of Rs 1,970.68 crore, up from Rs 1,770.68 crore in the corresponding quarter of the previous year. However, the company reported a loss of Rs 88.64 crore in the quarter, breaking its streak of three consecutive quarters of profits.
As of June 30, 2024, the promoters of Piramal Pharma held 34.95% stake in the company, down from 35.02% as of March 31, 2024. Domestic Institutional Investors (DIIs) held 12.95% stake, up from 12.12% as of March 31, 2024. Foreign Institutional Investors (FIIs) held 31.4% stake, up from 30.58% as of March 31, 2024.
Piramal Pharma’s Valuation Metrics
Piramal Pharma’s market capitalization stood at Rs 30,683 crore as of September 10, 2024. The company’s price-to-earnings (P/E) ratio was 1,148.5, while its price-to-book (P/B) ratio was 4. The stock’s 52-week range was Rs 88 to Rs 244.
Piramal Pharma’s Peer Comparison
Piramal Pharma competes with other pharmaceutical companies in India, such as Sun Pharma, Divi’s Labs, Cipla, and Torrent Pharma. As of September 10, 2024, Sun Pharma had a market capitalization of Rs 437,074.85 crore, Divi’s Labs had a market capitalization of Rs 135,227.04 crore, Cipla had a market capitalization of Rs 133,643.09 crore, and Torrent Pharma had a market capitalization of Rs 117,953.31 crore.
Piramal Pharma’s Future Outlook
Analysts remain cautious about Piramal Pharma’s future prospects, given the company’s low interest coverage ratio and low return on equity of 1.06% over the last three years. However, the company’s strong market position in the pharmaceutical industry and its diversified business segments, including contract development and manufacturing organizations (CDMO), complex hospital generics, and consumer healthcare, provide a strong foundation for future growth.
Disclaimer: The information given in this article is from investment experts and brokerage companies, they do not represent Local Haryana. Before taking any investment related decision, you must consult a certified expert.
